Loading company
Attovia Therapeutics, Inc.
ATTO · Nasdaq · ·
$18.12+2.8%Sep 29 close
- 1M
- -12.5%
- 6M
- +3,707.5%
- 1Y
- +3,707.5%
- 5Y
- -37.5%
ATTO · Nasdaq · ·
$18.12+2.8%Sep 29 close
From the company’s own 8-K filing.
Attovia Therapeutics, Inc. has no earnings call transcript available.
“Following the successful completion of our upsized IPO, Attovia enters its next exciting phase with a strong balance sheet and clear line of sight to multiple potential near-term value-creating milestones,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Attovia is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need. All of its product candidates have been internally discovered using its ATTOBODY biparatopic biologics platform. Attovia’s ATTOBODY platform uses an evolution-driven, high-throughput process that allows for rapid discovery and creation of a high diversity of potential product candidates. Attovia’s lead programs include ATTO-1310, an anti-IL-31 therapeutic in clinical development for chronic pruritic diseases; ATTO-2306, a bispecific antibody targeting IL-31 and IL-13 in IND-enabling studies for atopic dermatitis and other immune-mediated skin diseases; and ATTO-1091, a trispecific antibody targeting TL1A, IL-23p19, and integrin α4β7 in IND-enabling studies for inflammatory bowel disease. Attovia’s other programs include highly innovative conditional ‘AND’ gated bispecific immune cell survival blockers and multispecifics.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Attovia Therapeutics, Inc.’s Item 2.02 8-K filed September 2, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.